On February 22, 2021 New Horizon Health reported that $263 million IPO last week on the Hong Kong Exchange to support its early cancer screening tests (Press release, New Horizons Diagnostics, FEB 22, 2021, View Source [SID1234575417]). The stock tripled in trading, giving the company a market cap of $4.3 billion. New Horizon markets two stool based tests in China: ColoClear, a multi-target, FIT-DNA test aimed at people at risk for colorectal cancer, and Pupu Tube, a self-administered FIT test intended to screen a larger population. The company also has two late-stage product candidates for gastric and cervical cancer screening.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!